Mostrando postagens com marcador medicamento. Mostrar todas as postagens
Mostrando postagens com marcador medicamento. Mostrar todas as postagens

quarta-feira, 19 de junho de 2013

Moringa é o novo “milagre” dos que buscam medicamentos que curam tudo

MORINGA

A vontade de se libertar das enfermidades tem levado muitos doentes a aderirem aos remédios naturais. Os produtos são comercializados em vários pontos de Luanda, na zunga e nos mercados, mas a moringa é encontrada apenas nos portões dos hospitais de Luanda, sobretudo no Hospital Américo Boavida, Josina Machel e Hospital Militar, onde os comerciantes se concentram em maior número.
Diferentes do jola miongo, missange, jipepe e de outros medicamentos naturais já conhecidos no mercado nacional, as várias partes da moringa podem ser usadas para curar no mínimo 300 doenças, isto é o que afirma a comerciante Beatriz Gonçalves, com alguma solenidade. “Os medicamente todos são chamados de moringas, como a moringa sementes, moringa raízes e moringa em folha. Existe também o xarope de moringa, que resulta da efusão de uma mistura das folhas, flores, sementes e raíz da moringa, e à que se junta também alho, limão e mel, tudo nacional”, realçou.
“Moringa Santo Remédio” serve para tratar doentes com diabetes, miomas, febre tifoide e impotência sexual. Para além dessas doenças, a medicação com moringa pode sarar os enfermos com problemas de visão, dor de estômago, inflamações no corpo.
CANCRO DA MAMA NA LISTA
Particularmente para as mulheres, a moringa pode ajudar no tratamento do cancro da mama, infecções urinárias, cancro do útero, prisão de ventre. Tudo isso ainda nas palavras de Beatriz Gonçalves.
Ela também diz como se deve usar cada parte da planta: se for a parte da semente, o processo passa por tirar-lhes a casca e mastigar, ao mesmo tempo que se vai bebendo um copo de água. A medicação é feita três vezes ao dia, mastigando três sementes às sete da manhã, às 14 horas e, por último, às 22 horas. Se tiver de tratar-se com as folhas, deve-se fervê-las e tomar a infusão resultante em duas porções (equivalentes a 2 chávenas) por dia. Para o caso das raízes, deve-se ferver oito metades num litro de água e depois tomar três porções por dia. O xarope é tomado com uma colher de chá três vez ao dia. Este é o receituário, segundo D. Beatriz Gonçalves.
Com seis meses de negócio em frente ao Hospital Militar, Beatriz diz ter já muitos clientes.
A nossa “curandeira” de frente de hospital diz que um doente com febre tifóide deve tomar a medicação com sementes durante quinze dias.
A folha da moringa, diz ela, tem grande efeito na cura da hipertensão. Mas é também boa para curar a tosse em crianças. Já a moringa raiz faz bem, sobretudo, às mulheres com infecção urinária, aclarou.
Beatriz compra os produtos no Huambo,  em sacos de 50 quilos que custam 5 mil kwanzas. Quando vai vender, fá-lo em medidas pequenas,  e um quilo sementes é vendido  a mil kwanzas. Já moringa raiz custa 500 kwanzas, e a moringa folhas custa apenas 200 kwanzas. O negócio é rentável, num dia de vendas é possível facturar dez mil kwanzas.
O curioso é que Beatriz descobriu a planta por indicação de uma amiga indiana que conhecia a moringa no seu país e a veio reencontrar em Angola.
“Eu também consumo esses produtos e fui curada de um cancro. Os nossos maiores clientes são os doentes dos hospitais, muitos deles são recomendados pelos doutores, alguns médicos do Hospital Militar também têm comprado os nossos produtos porque são credíveis”, disse.
Uma outra mulher, Tânia Sebastião de Carvalho, vende a moringa há um ano em frente ao Hospital Militar. Diz ela que se sente bem, porque cada venda efectuada está “a curar pessoas e a devolver vida”. Tânia conta que começou a comercializar esses medicamentos quando viu os seus efeitos depois de uma prima os ter receitado para o seu filho que estava muito doente.
 Antes, Tânia não exercia outra actividade para ocupar o seu tempo. Ao contrário da “colega” Beatriz, os produtos de Tânia são adquiridos em Cacuaco.
GRÁVIDAS NÃO DEVEM TOMAR
Paulina Jambila, uma outra vendedora, diz que não recebe reclamações dos clientes. Ao contrário, os consumidores passam testemunhos positivos e surgem mais interessados em comprar. A medicação feita com a moringa está proibida para as mulheres gravidas, acrescenta, por se tratar de algo muito forte, já “para os homens com pouca potência sexual é aconselhado usar as sementes e as raízes da moringa”.     
“A doença no corpo do homem entra rápido, mas sai lentamente, a medicação deve ser feita constantemente. Muitos doentes apenas provam os medicamentos, neste caso a doença ou o vírus fica apenas murcho, quando ressuscita resulta em trombose, febre alta ou mesmo malária”, salientou a senhora.
A nossa interlocutora disse que vende os produtos naturais há três anos, em vários pontos de Luanda, mas é especificamente defronte aos hospitais que as coisas melhor correm. Actualmente vende para os doentes do Hospital Américo Boa Vida. A senhora explicou que quando se começa uma medicação deve-se continuar até ao dia determinado que são trinta dias. Durante a medicação com produtos naturais o doente não deve consumir bebidas alcoólicas nem beber água fresca. Não deve alimentar-se de frango importado nem carne congelada, apenas é recomendável comer “carne abatida” e peixe grelhado ou cozido, excluindo-se o frito, por causa da gordura que tem causado várias doenças.
Paulina Jambila revelou, entretanto, que neste negócio não estão apenas angolanos, a moringa que ela vende vem de uma companhia chinesa chamada Jenerdin, localizada no bairro do Cassenda, distrito da Maianga. “Mas os produtos são nacionais e aprovados por laboratórios da India”, defendeu.
RECEITAS SEM FIM
Cada vendedora tem a sua própria lista de doenças que são tratadas pela moringa e dos procedimentos para a cura. Em caso de intoxicação, o antídoto passa pela ingestão de “uma mistura de mel e carvão”, receitou a Paulina.
Para os homens com problemas de ejaculação precoce ou dor de rins, aconselha-se o chá feito com a raiz “para fazer uma limpeza no organismo”. Paulina diz que muitas doenças são consequências dos alimentos que consumimos.
Paulina Jambila disse ainda que a medicação com remédios naturais não  deve ser misturada com os fármacos modernos.  

Telma Van-Dúnem
8 de Abril de 2013

Medicamento pode aumentar libido em mulheres com disfunção sexual

Segundo pesquisadores, a FDA pode proibir a droga por medo de "excessos femininos" Foto: Getty Images
Segundo pesquisadores, a FDA pode proibir a droga por medo de "excessos femininos"
Foto: Getty Images
As mulheres que sofrem de disfunção do desejo sexual são incapazes de descobrir o que as fez parar de querer relações sexuais com o marido ou namorado.  O problema costuma atingir entre 10% e 15% do público feminino com idade entre 20 e 60 anos. Mas, o medicamento Lybrido pode ajudar a resolver o problema, segundo a revista Cosmopolitan.
Não é exatamente o “Viagra feminino”, pois, diferente da pílula masculina, o Lybrido trabalha com outras áreas de estímulo sexual, como partes do cérebro que cuidam dos impulsos sexuais e da falta deles. Um dos obstáculos ao criar um medicamento eficaz, no entanto, é a necessidade de mensurar quanto de libido falta na mulher.
Pesquisadores do Lybrido afirmaram que a droga funciona muito bem como um estimulante sexual para as mulheres, mas alertou que a FDA (Food and Drug Administration) pode proibi-la por medo de criar “excessos femininos”.

domingo, 9 de junho de 2013

Homens que tomam remédios têm 50% mais chance de ter disfunção erétil, revela estudo

16/5/2013 às 17h25 (Atualizado em 16/5/2013 às 17h32)

De acordo com estudo, substâncias usadas para tratar dores nas costas podem fazer mal

Homens que tomam analgésicos para dor nas costas têm 50% mais chances de terem disfunção erétil. É o que sugere uma nova pesquisa norte-americana publicada nesta terça-feira (15) na revista Spine.
De acordo com o autor da pesquisa, Richard A. Deyo, do Centro de Kaiser Permanente de Pesquisa em Saúde, os pacientes que tomam analgésico do tipo opioides (conhecidos como hidrocodona, oxicodona e morfina) por um longo período de tempo têm o maior risco de disfunção. Para chegar a esta conclusão, os estudiosos fizeram análise de registros de saúde de 11 mil pacientes.
Ainda segundo a pesquisa, homens com mais de 60 anos de idade têm mais chances de ter disfunção que os mais  jovens. Mais de 12% dos homens estudados que assumiram terem tomado opioides em baixas doses (com menos de 120 mg) durante pelo menos quatro meses sofriam de disfunção.
De acordo com Deyo, isso "não significa que esses medicamentos causam disfunção erétil, mas os pacientes e os médicos devem estar cientes de quando decidir se estas medicações devem ser usados ​​para tratar a dor nas costas".
— Não há dúvida de que para alguns pacientes o uso de opioides é apropriado, mas também há cada vez mais evidências de que o uso a longo prazo pode levar à dependência, overdoses fatais, apneia do sono, quedas em idosos, diminuição da produção de hormônios, e agora disfunção erétil.
Depressão e uso de sedativos hipnóticos, como os benzodiazepínicos também aumentaram a probabilidade do homem desenvolver a disfunção.

Medicamento pode aumentar libido em mulheres com disfunção sexual

Segundo pesquisadores, a FDA pode proibir a droga por medo de "excessos femininos" Foto: Getty Images
Segundo pesquisadores, a FDA pode proibir a droga por medo de "excessos femininos"
Foto: Getty Images
As mulheres que sofrem de disfunção do desejo sexual são incapazes de descobrir o que as fez parar de querer relações sexuais com o marido ou namorado.  O problema costuma atingir entre 10% e 15% do público feminino com idade entre 20 e 60 anos. Mas, o medicamento Lybrido pode ajudar a resolver o problema, segundo a revista Cosmopolitan.
Não é exatamente o “Viagra feminino”, pois, diferente da pílula masculina, o Lybrido trabalha com outras áreas de estímulo sexual, como partes do cérebro que cuidam dos impulsos sexuais e da falta deles. Um dos obstáculos ao criar um medicamento eficaz, no entanto, é a necessidade de mensurar quanto de libido falta na mulher.
Pesquisadores do Lybrido afirmaram que a droga funciona muito bem como um estimulante sexual para as mulheres, mas alertou que a FDA (Food and Drug Administration) pode proibi-la por medo de criar “excessos femininos”.
http://mulher.terra.com.br/vida-a-dois/medicamento-pode-aumentar-libido-em-mulheres-com-disfuncao-sexual,731602a4eb1de310VgnVCM10000098cceb0aRCRD.html

quinta-feira, 28 de fevereiro de 2013

Propecia Side Effects Studied By Independent Non-Profit Organization


Perry Larkin | February 19th, 2013 | Posted in Propecia Lawsuits

Propecia Erectile Dysfunction Side EffectsAn increasing number of lawsuits are being filed by a Propecia lawyer due to side effects from the medication manufactured by Merck to treat male pattern baldness. The number of patients to date who have filed cases alleging problems due to the medication has reached almost 400.
Some of these cases have been consolidated into multidistrict litigation (MDL) located in federal court. The MDL process is designed to streamline the cases, save time and money for the plaintiffs and the defendant, and prevent overlapping rulings.

Reported side effects for Propecia can be serious

The Propecia side effects listed in these complaints have included shrinkage, testicular pain, erectile dysfunction, and long-term sexual side effects. Other reported side effects have included:
• Psychological problems
• Problems with ejaculation
• Diminished or lost libido
• Failure of the endocrine system
• Peyronie’s disease (penile curvature)
• Cancer of the prostate
• Male breast cancer

ISMP releases report on Propecia

The Institute for Safe Medication Practices (ISMP) released their regular report regarding medications that are considered dangerous on January 9, 2013. Discussed in the report is Propecia (finasteride).
It notes that Propecia side effects such as erectile dysfunction can become permanent. The report also notes a 40-month study that showed that side effects from the medication can persist even after it is discontinued by the patient. Continued side effects are the most concerning factors with the drug.
A 1997 review stated that Merck and the Food and Drug Administration (FDA) the sexual side effects would, predominately, cease upon discontinuation of its use. This belief was based on a clinical study over the course of six months to a year. The ISMP stated that the follow up was unclear and it is possible that the drug causes enduring changes in the prostate and can potentially lead to long-term reductions in sexual desire and function. ISMP stated that it’s likely that the medication can result in long-term and perhaps permanent side effects like erectile dysfunction.
ISMP is calling for more research into Propecia complications.

Many side effects of Propecia said to be long-term

The ISMP has been in existence for more than 35 years and is a non-profit, respected organization that investigates safe prescription practices and medicinal error prevention. In its QuarterWatch report, the ISMP releases its independent reviews and compiles date submitted to the FDA during the second quarter of 2012.
In the report, alleged side effects of Propecia were reviewed.
50,289 adverse events reports were submitted to the FDA and 61 reports of substantial side effects were made in the second quarter of 2012. 46 of the adverse events were related to sexual side effects. 71% of them claimed a “significant or long-term disability.”
Side effects included gynecomastia (male breast enlargement), pain of the scrotum, and testicular pain. Also included were reports of testicular shrinkage, decreased size of penis, Peyronie’s disease, and anorgasmia. The ISMP reported that the sexual side effects were serious enough that the FDA updated the prescribing information for Propecia.
- See more at: http://injurylawyer-news.com/2013/02/propecia-side-effects-studied-by-independent-non-profit-organization/#sthash.pMjfq4o9.dpuf

Columbus Center for Women’s Health Research is participating in an International Study for a New “Use-as-Needed” Treatment for Women with Sexual Dysfunction



>PRWEB.COM Newswire
Columbus, OH (PRWEB) February 23, 2013
Female Sexual Dysfunction affect women worldwide. Columbus Center for Women’s Health Research or CCWHR is participating in one of the largest clinical studies to ever explore a “use-as-needed” treatment, Tefina™, for women experiencing orgasmic disorder. The study, which will involve 240 patients in the U.S., Canada and Australia, will evaluate if there is an increase in the occurrence of orgasm over the treatment period, compared against baseline levels.
Recently there has been a lot of media coverage surrounding this study with references to Tefina as “female-viagra”. Tefina™ is a nasal gel containing bio-identical testosterone and is gently placed on the inside wall of the nose with an easy to use applicator 1-4 hours before sexual activity. The gel is designed to adhere to the nasal wall and not drip out, allowing the testosterone to be absorbed through the nasal lining within 10-15 minutes of application. Female Orgasmic Disorder, also known as Female Anorgasmia, is defined as the persistent or recurrent delay in or absence of orgasm. Although this condition is estimated to affect up to 1 in 5 women worldwide, there are no FDA approved treatments.
“Tefina™ is a potentially revolutionary treatment to restore women’s ability to obtain orgasm and sexual satisfaction” says Dr. Kingsberg, Primary Investigator of the study and Chief of Behavioral Medicine at UH MacDonald Women’s Hospital. “Low sexual satisfaction is linked to a lower sense of well-being as well as to tension in relationships. We are hopeful that this be a real help for patients who say ‘sex has become a chore.’
Participants must be aged 18 to 65 and be unable to be sexually satisfied after previously having had no problems. David J. Portman, MD is the PI for the local trial site at Columbus Center for Women’s Health Research. Dr. Portman founded the Columbus Center for Women's Health Research in 1997 and has conducted many clinical studies in hormone therapy, osteoporosis, contraception, endocrine and heart disease and other issues pertaining to OB/GYN. In addition, he is recognized as one of the country's leading experts in menopause and the treatment options available to women today. He lectures extensively across the country on this and related topics, and frequently consults on issues related to Women's Health. For more information on current studies, call 614-861-6707 or visit http://www.ccwhr.com


Read more: http://www.digitaljournal.com/pr/1089088#ixzz2MDwPOsFL
 - See more at: http://www.digitaljournal.com/pr/1089088#sthash.nrQiCoU4.dpuf

quinta-feira, 24 de janeiro de 2013

RJ: Justiça proíbe clínica de fornecer produtos para impotência sexual

23 de Janeiro de 2013  00h38

Atendendo a requerimento do Ministério Público do Rio de Janeiro, o Juízo da 1ª Vara Empresarial da Capital antecipou a proposta que determina que a clínica Arte-Cleaner Clínicas Médicas (ProMem) deixe  imediatamente de fornecer medicamentos aos seus pacientes para uso fora do estabelecimento, sob pena de multa diária de R$ 1 mil.
Um inquérito da Justiça de Defesa do Consumidor investiga “se a clínica que atende na área de saúde masculina estava desempenhando atividade irregular de comercialização de medicamentos ao fornecer aos pacientes produtos produzidos mediante manipulação, tais quais injetáveis para inoculação no tecido peniano, bem como sprays para ejaculação precoce”.
Ao subscrever a inicial da ação, o Promotor de Justiça Júlio Machado Teixeira Costa destacou que a própria clínica se manifestou no inquérito civil reconhecendo que parte do tratamento envolve procedimento com a administração de medicamentos feita em casa pelo próprio paciente que recebe os mesmos do próprio estabelecimento.
O Ministério Público salientou que a irregularidade foi detectada em inspeções realizadas pelo Cremerj e pela Vigilância Sanitária Municipal, e acrescentou que de acordo com o artigo sexto da Lei 5991/73 (dispõe sobre o Controle Sanitário do Comércio de Drogas), “não é possível que uma mera clínica médica, sem farmácia ou dispensário de medicamentos faça a dispensa direta ao consumidor.”
Em sua decisão, o Juiz de Direito da 1ª Vara Empresarial, Luiz Roberto Ayoub, concluiu que "pela análise dos autos, a atitude da ré representa burla ao sistema de proteção sanitária criado em benefício do consumidor”. Ele considerou ainda que a permanência da irregularidade poderá acarretar danos aos consumidores que procuram  a clínica com objetivo terapêutico”.
Na ação, o MPRJ requer ainda que a clínica seja condenada a indenizar os danos materiais e  morais causados aos consumidores, quer individual e coletivamente, neste último caso no valor de R$ 300 mil.

http://noticias.terra.com.br/brasil/rj-justica-proibe-clinica-de-fornecer-produtos-para-impotencia-sexual,addf340bd356c310VgnVCM20000099cceb0aRCRD.html

terça-feira, 8 de janeiro de 2013

5 medicamentos que podrían atentar contra tu vida sexual


08 de enero de 2013  11:15
Partimos de la base que los medicamentos son necesarios y ayudan a aliviar dolores y a mejorar nuestra salud física y mental. Sin embargo, en algunos casos, su consumo, especialmente el crónico, genera efectos secundarios nocivos en la vida sexual tanto de hombres como mujeres.
Falta de deseo o disminución de la libido, anorgasmia, disfunción eréctil, sequedad vaginal y eyaculación tardía, son algunas de los males sexuales más comunes que podrían generar en algunas personas (no en todas) el consumo de determinados fármacos.
Advertencia: De divisar algunos cambios en la sexualidad por el consumo de fármacos, es aconsejable acudir hasta el médico tratante, ya que es el único indicado para analizar el caso y dar una solución que puede ir desde bajar la dosis o hasta cambiar el tipo de medicamento. Bajo ningún caso, es aconsejable dejar de lado el tratamiento, ya que una solución de este calibre podría poner en riesgo tu salud y hasta tu vida.
A continuación te damos un listado de algunos tipos de fármacos en que se han reportado efectos negativos en la vida sexual de los pacientes. La buena noticia, es que son casos minoritarios, pero hay que estar informadas.
Antidepresivos
Función: Medicamentos para el tratamiento de depresiones y/o  trastornos de la ansiedad y que se dividen en diversos grupos de acuerdo a las sustancias químicas del cerebro que afectan. Actúan a nivel del sistema nervioso central.
Posible efecto nocivo en el sexo: Son conocidos por producir alternaciones en la vida sexual de quien los consume. En algunos casos provocan anorgasmia, y en otros falta de erección y apetito sexual. Por lo mismo, es de vital importancia indicarle al médico tratante si es que se padecen de estos efectos secundarios tras consumir este tipo de fármacos.
Antihipertensivos
Función: Tal como indica su nombre, son medicamentos para tratar la hipertensión arterial.
Posible efecto nocivo en el sexo: Se trata de un grupo de fármacos que tiene efectos en la circulación sanguínea y que puede provocar trastornos  en el funcionamiento sexual, siendo los más frecuentes: disminución del deseo, escasa lubricación vaginal en las mujeres e impotencia en los hombres.
Relajantes musculares
Función: Alivian tensión en los músculos, tienen efecto analgésico y antiinflamatorio.
Posible efecto nocivo en el sexo: Si bien consumirlos es algo bastante común cuando aflora algún dolor de espalda o de otra índole, pocos sabe que estos, en algunas personas, provocan de manera temporal disfunciones sexuales y afecta la capacidad eréctil de los hombres.
Ansiolíticos
Función: Tranquilizantes menores que son usados para bajar los niveles de ansiedad y nerviosismo. También son recetados para personas que tienen problemas para dormir.
Posible efecto nocivo en el sexo: Se han registrado casos de disminución de la libido tanto en hombres como mujeres, en éstas últimas, muchas veces se presenta como falta de lubricación. Aunque también muchas veces esto es temporal, ya que el cuerpo tiende a adaptarse al medicamento en la mayoría de los casos.
Antivirales
Función: Grupo de medicamentos utilizados para el tratamiento de infecciones provocadas por un virus.
Posible efecto nocivo en el sexo: Se han reportado casos de impotencia y también de disminución de la libido.
Consejos prácticos y vitales
*No dejar por cuenta o decisión propia el medicamento aún cuando se noten trastornos en la sexualidad, ya que existe la posibilidad que el problema sexual no sea por el fármaco sino que por la enfermedad en sí. El indicado para analizar el caso es el médico tratante.
*Acudir lo antes posible ante un médico y detallar los cambios. Intentar mantener una buena comunicación y relación con el especialista.
*Evitar a toda costa  auto medicarse. No se debe ingerir ningún tipo de medicamento sin supervisión médica.
*En caso de tener pareja, mantener una buena y sincera comunicación con ella respecto al tema. 
http://vidayestilo.terra.cl/mujer/amor/5-medicamentos-que-podrian-atentar-contra-tu-vida-sexual,fabe820153a1c310VgnVCM5000009ccceb0aRCRD.html

domingo, 4 de novembro de 2012

Is 'female Viagra' coming soon?


  • FEMALE VIAGRA
  • NOVEMBER 2, 2012
  • BY: TOM ROSE


  • "Female Viagra" which goes by the trademark "Tefina" will be tested soon on women in Canada and Australia, according to a medical report released earlier this week.
    The clinical trial may pave the way in the US for a long awaited counterpart to the phenomenally successful sexual performance drug (male Viagra?) prescribed to men for the last 14 years.
    The medication is not an exact opposite of the male sexual enhancement stimulant. Tefina, instead of increasing female hormones, boosts testosterone, in this case with a gel, absorbed through a nasal applicator, rather than just popping a "little blue pill" as men do.
    But, according to an article published on theGlamour sex and love blog on Thursday, this new drug will not cause side effects in women, like a booming voice or increased body hair.
    The medication treats female sexual dysfunction, known as anorgasmia (the inability to achieve orgasm) and, according to Monday's Medical Daily, women have already begun trials in the United States.
    Successful results could mean American women may be one step closer to the same kind of treatment for lowered libido which men have flocked to, and had great success with, since Viagra became available on the US market in 1998.
    Could this just be a gimmick thought up by the drug companies salivating over the untapped half of the patient pool?
    Not according to Dr. Fiona Jane of Melbourne's Monash University in Australia.
    "A lot of people have thought that drumming up the idea of a female 'Viagra' is just for pharmaceutical companies" she told New Zealand's One News. "In fact, there is a huge need for women to have their sexual dysfunction addressed."
    If this new drug is half as successful as Viagra has been, women may soon be able to enjoy sex more, a state of mind and body thought to be a key factor leading to an increased sense of well-being.
    It's interesting that Tefina is administered nasally. Perhaps by the time the drug hits the American market it will be sold in a more familiar form.
    Is the world about to enter the age of the little pink pill?
    What do you think? Will American women try Tefina, if it goes to the market? How will men react to a "female Viagra"?

    quarta-feira, 26 de setembro de 2012

    Receita Federal apreende mais de 17 mil comprimidos para disfunção erétil


    25/09/12 às 15:11 Redação Bem Paraná


    Na manhã desta terça-feira (25), a equipe de fiscalização da Receita Federal em Foz do Iguaçu encontrou muitos medicamentos em uma operação de fiscalização de bagagens. Foram 17.600 comprimidos para disfunção erétil, 145 ampolas e 84 frascos de anabolizantes, 3.590 comprimidos e 15 ampolas de emagrecedores, além de 1.480 comprimidos de substância abortiva.
    O material vistoriado foi apreendido em ação realizada no âmbito da Operação Fronteira Blindada no último dia 20/09. Na ocasião, servidores da Receita Federal, com o apoio da Polícia Rodoviária Federal (PRF), realizaram a apreensão de diversos volumes de mercadorias provenientes do Paraguai em um ônibus que fazia a linha Foz – Londrina, no posto de fiscalização da PRF em Santa Terezinha de Itaipu/PR.
    Com base nas informações colhidas no momento da apreensão, foi possível identificar o proprietário dos produtos. Ele será representado penalmente ao Ministério Público Federal, ficando sujeito a ação penal pelo crime de contrabando de medicamentos, cuja pena mínima é de 10 anos de reclusão.

    http://www.bemparana.com.br/noticia/231452/receita-federal-apreende-mais-de-17-mil-comprimidos-para-disfuncao-eretil

    segunda-feira, 27 de agosto de 2012

    Cirurgião testa o uso do produto em mulheres que sentem dor durante o sexo

    Novo teste com botox - 04/08/2012 às 08:15h

    A doença provoca contrações involuntárias na musculatura genital, gerando dor e queimação

    Queridinho de homens e mulheres que lutam contra as rugas do envelhecimento, o botox pode também ser um aliado na cama. Estudos clínicos feitos por um médico americano mostraram bons resultados do uso da toxina botulínica em mulheres que sofrem com vaginismo. A doença provoca contrações involuntárias na musculatura genital, gerando dor e queimação. Cerca de 5% da população feminina sofre com o problema, que pode até impedir a penetração.
    — Se esse estudo ficar mesmo comprovado, as perspectivas de aliviar o sofrimento das pacientes serão muito positivas. Vejo como uma ótima novidade — comemora o cirurgião plástico Ricardo Cavalcanti.
    A técnica em teste consiste na aplicação da toxina botulínica nos músculos da entrada da vagina. A substância interrompe a passagem dos impulsos nervosos. Como consequência, a região fica mais relaxada e a vida sexual, mais prazerosa. Segundo os pesquisadores, cerca de 80 voluntárias participaram dos testes; apenas uma não apresentou melhora. As análises continuam sob supervisão da FDA, agência americana que controla alimentos e medicamentos. No Brasil, ainda não há autorização para estudos.
    Entre as causas para o vaginismo estão traumas emocionais e uma criação muito repressiva com relação à sexualidade.

    quarta-feira, 22 de agosto de 2012

    Cirurgião testa uso do botox em mulheres que sentem dor durante o sexo

    03/08/2012 - 05h11
    Thamyres Dias | Extra Online
    Queridinho de homens e mulheres que lutam contra as rugas do envelhecimento, o botox pode também ser um aliado na cama. Estudos clínicos feitos por um médico americano mostraram bons resultados do uso da toxina botulínica em mulheres que sofrem com vaginismo. A doença provoca contrações involuntárias na musculatura genital, gerando dor e queimação. Cerca de 5% da população feminina sofre com o problema, que pode até impedir a penetração.
     
    — Se esse estudo ficar mesmo comprovado, as perspectivas de aliviar o sofrimento das pacientes serão muito positivas. Vejo como uma ótima novidade — comemora o cirurgião plástico Ricardo Cavalcanti.
     
    A técnica em teste consiste na aplicação da toxina botulínica nos músculos da entrada da vagina. A substância interrompe a passagem dos impulsos nervosos. Como consequência, a região fica mais relaxada e a vida sexual, mais prazerosa. Segundo os pesquisadores, cerca de 80 voluntárias participaram dos testes; apenas uma não apresentou melhora. As análises continuam sob supervisão da FDA, agência americana que controla alimentos e medicamentos. No Brasil, ainda não há autorização para estudos.
     
    Entre as causas para o vaginismo estão traumas emocionais e uma criação muito repressiva com relação à sexualidade.

    Trimel Announces Second Quarter 2012 Financial Results and Provides Product Development Update


    Marketwire - Canada

    TORONTO, ONTARIO--(Marketwire - Aug. 7, 2012) - Trimel Pharmaceuticals Corporation (TSX:TRL) ("Trimel or "the Company") today reported its financial results for the three and six month periods ended June 30, 2012. The Company also provided investors today with an update on the status of its product development programs.
    Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Wednesday, August 8, 2012, at 8:30 a.m. Eastern Daylight Time. Presenting from Trimel will be Bruce Brydon, Chairman of the Board and Chief Executive Officer, Tom Rossi, President and Chief Operating Officer and Kenneth Howling, Chief Financial Officer. The conference call details can be found at the end of the press release.
    Financial Results for the Three and Six Months Ended June 30, 2012
    For the three and six month periods ended June 30, 2012, Trimel incurred Research and Development expenses ("R&D") of US$4.8 million and US$9.1 million respectively as compared to US$2.9 million and US$4.7 million for the comparable 2011 periods. The increase in R&D spending for the 2012 period relates primarily to the costs associated with the advancement of the CompleoTRT(TM) Phase III clinical trial.
    Trimel incurred General and Administrative expenses of US$2.6 million and US$4.8 million for the three and six month periods ended June 30, 2012 respectively as compared to US$1.3 million and US$3.2 million for the comparable 2011 periods. The increase in spending for the 2012 period as compared to spending levels for the same 2011 period was primarily attributable to employment related expenses, professional fees and public company costs following the Company's successful 'go public' transaction in July 2011.
    For the three and six month periods ended June 30, 2012, the Company incurred a net loss of US$0.09 and US$0.17 per share respectively, as compared to US$0.10 and US$0.19 per share for the comparable 2011 periods.
    As at June 30, 2012, the Company had total assets of US$12.1 million as compared to US$17.6 million at March 31, 2012 and total liabilities of US$6.7 million at June 30, 2012 as compared to US$5.6 million at March 31, 2012. Subsequent to June 30, 2012the Company completed two financing transactions raising total gross proceeds of US$20.6 Million (see "Corporate Update" section below).
    The information set out above is in summary form. Readers are encouraged to review the Company's annual information form, financial statements (and accompanying notes), together with management's discussion and analysis available on SEDAR at www.sedar.com.
    Product Development Update
    CompleoTRT(TM) (Testosterone - Hypogonadism ("Low T"))
    Phase III Enrolment Completed
    On July 23, 2012, the Company announced the completion of enrolment and randomization of 304 patients in the Phase III clinical trial evaluating CompleoTRT(TM). The pivotal Phase III clinical trial, which was initiated in October 2011, is a randomized study in which patients are administered CompleoTRT(TM) and evaluated for efficacy after 90 days of treatment using the pharmacokinetic endpoint established for Low T therapies. The Phase III study in its entirety represents the final stage of product development prior to the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for marketing approval in the United States.
    Efficacy results from the Phase III clinical trial are expected to be available in the fourth quarter of 2012. As previously announced on May 29, 2012, the preliminary review of early data from the Phase III trial demonstrated that patients treated with CompleoTRT(TM) achieved an average serum testosterone level that exceeds the threshold required by the FDA to confirm the efficacy of a testosterone replacement product.
    Testosterone Market Dynamics - Second Quarter 2012
    According to IMS Health, nearly 1.7 million testosterone prescriptions were written in the second quarter of 2012, reflecting growth of 37% versus the same period in 2011. This represents an acceleration of prescription growth rates as physicians and patient awareness of this medical condition increases.
    Tefina(TM) (Testosterone - Female Orgasmic Disorder)
    Enrolment initiated for 240 Patient Ambulatory Study
    On May 17th, 2012, the Company announced the initiation of patient enrolment into one of the largest clinical studies to ever explore a "use-as-required" treatment for women experiencing Female Orgasmic Disorder ("FOD"), or more commonly referred to as Anorgasmia. FOD is defined as the persistent or recurrent delay in, or absence of, orgasm following a normal sexual excitement phase which can result in marked personal distress or interpersonal difficulties. FOD affects 1 in 5 women worldwide. Currently there are no approved treatments for FOD and therefore this condition represents a significant unmet need for women suffering distress from this condition.
    The Company intends to enrol 240 patients in this Phase II study being initiated in the United States, with additional sites in Canada and Australia expected to join the study in the second half of 2012. The Tefina(TM) Phase II study design will involve pre-menopausal women experiencing FOD and will be conducted as an ambulatory trial. As part of this double-blinded placebo-controlled study, patients will receive Tefina(TM) or placebo at home instead of in a hospital setting. The primary efficacy endpoint of the ambulatory trial will be the increase in the occurrence of orgasm over the treatment period compared against baseline levels.
    Corporate Update Equity Financing
    On July 17th, 2012 the Company announced that it had closed a public offering for aggregate gross proceeds of C$13.2 Million. In connection with the offering the Company issued 7,569,000 units ("Units") at a price of C$1.75 per Unit. Each Unit consists of one common share of the Company ("Common Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each whole Warrant entitles the holder to purchase one Common Share at an exercise price of C$2.50 until January 17, 2015.
    The Offering was completed by a syndicate of underwriters led by RBC Dominion Securities Inc. and including GMP Securities L.P. On July 31, 2012, RBC Dominion Securities Inc. and GMP Securities L.P. exercised in part their over-allotment option to purchase an additional 60,400 Trimel Common Shares and 74,700 Trimel Warrants for aggregate gross proceeds of C$111,040. The closing of the over-allotment took place on August 3, 2012.
    Debt Financing
    On July 18, 2012, the Company had entered into a loan and security agreement with GE Capital, Healthcare Financial Services ("GE Capital"), as agent for the lenders party thereto, pursuant to which GE Capital advanced U.S. $7,500,000 (the "Loan") to the Company. According to the Loan Agreement, the Loan accrues interest at 10.75% per year and is repayable in scheduled instalments through to July 1, 2015 (subject to repayment on demand at any time should certain customary events of default occur). As is customary, the Company has granted security over the assets of the Company and its subsidiaries. In connection with the transaction, the lenders under the Loan Agreement (or certain of their affiliates) have been issued warrants exercisable for an aggregate of 154,916 Common Shares of the Company and certain brokers have been issued warrants exercisable for an aggregate of 51,639 common shares of the Company. The warrants are exercisable for five years at an exercise price calculated using the volume weighted average trading price of the Common Shares on the Toronto Stock Exchange for the period of five days ending immediately prior to the completion of the Loan.
    Conference Call Details
    To access the call live, please dial 416-340-2216 (Toronto), 1-866-226-1792 (Canada and U.S.), and 00-800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.
    A replay of the conference call will be available until 7:00 p.m. Eastern Daylight Time on Tuesday, August 14, 2012 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 2484026#.
    About CompleoTRT(TM)
    CompleoTRT(TM) is designed to represent a significant advancement in the treatment of male hypogonadism, or low testosterone - commonly known as "Low T". CompleoTRT(TM)'s unique delivery technology is designed to provide patients with the therapeutic effect of supplementing testosterone levels while doing so with a small amount of drug in the form of a bio-adhesive intranasal gel.
    CompleoTRT(TM)'s intranasal no-touch delivery system is designed to avoid the risk of accidental transfer (primary or secondary transference) of testosterone to spouses or other family members, thus offering unique patient benefits and improved safety as compared to other currently marketed products indicated to treat "Low T".
    Since Trimel took over development of the product in the second half of 2009, CompleoTRT(TM) has been optimized to meet FDA regulatory requirements, including the development of a product dispenser that is designed to ensure that CompleoTRT(TM) is dosed accurately and discretely. Trimel has now successfully manufactured over 60,000 multi-dose dispensers. Trimel's CompleoTRT(TM) clinical program, having previously demonstrated that CompleoTRT(TM) is safe and effective in a Phase II trial, has recorded over 10,000 drug exposures in the studies conducted thus far in the United States.
    About Hypogonadism ("Low T")
    Subject to FDA approval, Trimel's lead product candidate, CompleoTRT(TM) would be indicated for the treatment of male hypogonadism or low testosterone - commonly known as "Low T". Hypogonadism is a biochemical syndrome characterized by a deficiency in serum testosterone levels that can be either acquired or inherited, and seriously affects the quality of life for those affected with the syndrome. Low testosterone is estimated to affect 13 million men in the United States, of which an estimated 90% go untreated. According to IMS Health, sales of marketed treatments for low testosterone in the United States grew 24% in 2011 versus 2010 to now exceed $1.6 billion in annual sales volume.
    About Tefina(TM)
    Trimel's product candidate Tefina(TM) is a bioadhesive 'no touch' intranasal low-dose gel formulation of testosterone. Tefina(TM) is being developed to offer women with anorgasmia, a "use as required" treatment option. Tefina(TM) is expected to present an attractive safety profile, with virtually no androgen-related side effects such as acne, facial and body hair growth or deepening of the voice. Moreover, there is no expected risk of skin-to-skin transfer of testosterone to third parties with the multi-dose dispenser.
    About Female Orgasmic Disorder
    Female Orgasmic Disorder ("FOD") is defined as the persistent or recurrent delay in, or absence of, orgasm following normal sexual excitement phase that causes marked personal distress or interpersonal difficulties. The etiology of FOD is often characterized by whether the dysfunction has been lifelong (primary) or acquired (secondary). This condition affects 1 in 5 pre and post menopausal women worldwide. Currently there are no approved treatments for FOD and therefore represents an unmet need for women suffering distress from this condition.
    About Trimel
    Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT(TM), a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT(TM) is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com.
    For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon, Chairman of the Board and Chief Executive Officer at (416) 679-0711 or Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at ir@trimelpharmaceuticals.com.

    segunda-feira, 16 de julho de 2012

    Trimel Hosts Tefina(TM) Investigator Meeting


    PRESS RELEASE
    June 18, 2012, 7:02 a.m. EDT

    TORONTO, ONTARIO, Jun 18, 2012 (MARKETWIRE via COMTEX) -- Trimel Pharmaceuticals Corporation ("the "Company" or "Trimel") announced today that the Company recently hosted a two day meeting in Chicago with leading investigators in the study of new treatments for Female Sexual Dysfunction. The purpose of the meeting was to allow the Company to review the trial protocol for the Company's ambulatory ("AMB") Phase II clinical study investigating the use of Tefina(TM) for the treatment of Female Orgasmic Disorder ("FOD"), or more commonly referred to as anorgasmia. The Company also used the meeting to train clinical study coordinators to ensure consistent patient selection and diagnosis, as well as discuss strategies for optimal study conduct.



    The Company intends to enroll 240 patients in its AMB Phase II study being initiated in both the United States and Canada, with additional sites in Australia expected to join the study in the third quarter of 2012. The primary efficacy endpoint of this ambulatory trial will be the increase in the occurrence of orgasm over the treatment period compared against baseline levels. Patients will receive Tefina(TM) or placebo at home instead of in a hospital setting.
    The principal investigator for this study is Dr. Sheryl Kingsberg. Dr. Kingsberg is the Chief of Behavioral Medicine at University Hospitals Case Medical Center and Professor in Reproductive Biology and Psychiatry at Case Western Reserve University in Cleveland, Ohio. Dr. Kingsberg's primary research interests are in treatments for female sexual disorders and the psychological aspects of infertility and menopause. She is an active member in a number of national and international scientific organizations and is a past president of the International Society for the Study of Women's Sexual Health.
    "I am pleased to have the opportunity to contribute my expertise to the design, planning and conduct of the Tefina(TM) ambulatory trial." said Dr. Kingsberg. "Women with Female Orgasmic Disorder have no approved pharmacological treatment options and Tefina(TM)'s innovative 'use as required' treatment approach, if approved, would help address this unmet need."
    "It was quite encouraging to hear positive feedback from such an esteemed group of leading clinicians in the treatment of Female Orgasmic Disorder" said Bruce D. Brydon, Chairman and Chief Executive Officer. "In particular, we found tremendous enthusiasm for the first 'use-as-required' approach provided by Tefina(TM) to treat a condition which is estimated to affect one in five women worldwide."
    About Tefina(TM)
    Trimel's product candidate Tefina(TM) is a bioadhesive 'no touch' intranasal low-dose gel formulation of testosterone. Tefina(TM) is being developed to offer women with female orgasmic disorder, a "use as required" treatment option. Tefina(TM) is expected to present an attractive safety profile, with virtually no androgen-related side effects such as acne, facial and body hair growth or deepening of the voice. Moreover, there is no expected risk of skin-to-skin transfer of testosterone to third parties with the multi-dose dispenser.
    About Female Orgasmic Disorder
    Female Orgasmic Disorder (FOD) is defined as the persistent or recurrent delay in, or absence of, orgasm following normal sexual excitement phase that causes marked personal distress or interpersonal difficulties. The etiology of FOD is often characterized by whether the dysfunction has been lifelong (primary) or acquired (secondary). This condition affects 1 in 5 pre and post menopausal women worldwide. Currently there are no approved treatments for FOD and therefore represents an unmet need for women suffering distress from this condition.
    About Trimel
    Trimel Pharmaceuticals Corporation - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT(TM), a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT(TM) is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com .
    For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon, Chairman of the Board and Chief Executive Officer at (416) 679-0711 or Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at ir@trimelpharmaceuticals.com.
    Notice regarding forward-looking statements:
    This release contains forward looking information. This forward-looking information is not based on historical facts but rather on the expectations of the Company's management regarding the future growth of the Company and its respective results of operations, performance and business prospects and opportunities. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives or economic performance, or the assumptions underlying any of the foregoing. This release uses words such as "will", "expects", "anticipates", "intends", "estimates", or similar expressions to identify forward-looking information. Such forward-looking information reflects the current beliefs of the Company's management based on information currently available to them.
    Forward-looking information included in this release is based in part, on assumptions that may change, thus causing actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking information. Such assumptions include that: the Company will achieve, sustain or increase profitability, and will be able to fund its operations with existing capital, and/or it will be able to raise additional capital to fund operations; the Company will be able to attract and retain key personnel; the Company will be able to acquire any necessary technology or businesses and effectively integrate such acquisitions; the Company will be successful in developing and clinically testing products under development; the Company will be successful in obtaining all necessary approvals for commercialization of its products from the U.S. Food and Drug Administration, the Canadian Therapeutic Products Directorate or other regulatory authorities; the results of continuing and future safety and efficacy studies by industry and government agencies relating to the Company's products will be favourable; the Company's products will not be adversely impacted by competitive products and pricing; raw materials and finished products necessary for the Company's products will continue to be available; the Company will be able to maintain and enforce the protection afforded by any patents or other intellectual property rights; the Company's products will be successfully licensed to third parties to market and distribute such products on favourable terms; the Company's key strategic alliances, out licensing and partnering arrangements, now and in the future, will remain in place and in force; the general regulatory environment will not change in a manner adverse to the business of the Company; the tax treatment of the Company and its subsidiaries will remain constant and the Company will not become subject to any material legal proceedings. The Company cautions that the foregoing list of assumptions is not exhaustive.
    Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results, performance or achievement could differ materially from that expressed in, or implied by; any forward-looking information in this release, and, accordingly, investors should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made and the Company undertakes no obligation to update any forward-looking information to reflect the occurrence of unanticipated events, except as required by law including applicable securities laws. New factors emerge from time to time and the importance of current factors may change from time to time and it is not possible for management of the Company to predict all of such factors, changes in such factors and to assess in advance the impact of each such factor on the business of the Company or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information contained in this release.
            
            Contacts:
            Trimel Pharmaceuticals Corporation
            Kenneth G. Howling
            Chief Financial Officer
            416 679 0536
            ir@trimelpharmaceuticals.com
     
    www.trimelpharmaceuticals.com    

    http://www.marketwatch.com/story/trimel-hosts-tefinatm-investigator-meeting-2012-06-18-7173137